{"id":996,"date":"2021-04-30T12:51:09","date_gmt":"2021-04-30T12:51:09","guid":{"rendered":"https:\/\/nclinnovations.org\/covid19monitor\/?p=996"},"modified":"2021-04-30T12:51:09","modified_gmt":"2021-04-30T12:51:09","slug":"20-apr-2021-epabs-inm005-mortality-was-69-the-inm005-group-vs-114-in-the-placebo","status":"publish","type":"post","link":"https:\/\/nclinnovations.org\/covid19monitor\/20-apr-2021-epabs-inm005-mortality-was-69-the-inm005-group-vs-114-in-the-placebo\/","title":{"rendered":"(20 Apr 2021) EpAbs (INM005)- mortality was 6*9% the INM005 group Vs 11*4% in the placebo"},"content":{"rendered":"<div class=\"boldgrid-section\">\n<div class=\"container\">\n<div class=\"row\">\n<div class=\"col-md-12 col-xs-12 col-sm-12\">\n<p class=\"\">RBD-specific polyclonal F(ab )2 fragments of equine antibodies in patients with moderate to severe COVID-19 disease: A randomized, multicenter, double-blind, placebo-controlled, adaptive phase 2\/3 clinical trial<\/p>\n<p class=\"\">https:\/\/doi.org\/10.1016\/j.eclinm.2021.100843<\/p>\n<p class=\"\">NCT04494984-Enrolled patients were assigned to receive two blinded doses of INM005 (n = 118) or placebo (n = 123). Median age was 54 years old, 65*1% were male and 61% had moderate disease at baseline. Median time from symptoms onset to study treatment was 6 days (interquartile range 5 to 8). No statistically significant difference was noted between study groups on primary endpoint (risk difference [95% IC]: 5*28% [-3*95; 14*50]; p = 0*15). Rate of improvement in at least two categories was statistically significantly higher for INM005 at days 14 and 21 of follow-up. Time to improvement in two ordinal categories or hospital discharge was 14*2 (+\/- 0*7) days in the INM005 group and 16*3 (+\/- 0*7) days in the placebo group, hazard ratio 1*31 (95% CI 1*0 to 1*74). Subgroup analyses showed a beneficial effect of INM005 over severe patients and in those with negative baseline antibodies. Overall mortality was 6*9% the INM005 group and 11*4% in the placebo group (risk difference [95% IC]: 0*57 [0*24 to 1*37]). Adverse events of special interest were mild or moderate; no anaphylaxis was reported. Albeit not having reached the primary endpoint, we found clinical improvement of hospitalized patients with SARS-CoV-2 pneumonia, particularly those with severe disease.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>RBD-specific polyclonal F(ab )2 fragments of equine antibodies in patients with moderate to severe COVID-19 disease: A randomized, multicenter, double-blind, placebo-controlled, adaptive phase 2\/3 clinical trial https:\/\/doi.org\/10.1016\/j.eclinm.2021.100843 NCT04494984-Enrolled patients were assigned to receive two blinded doses of INM005 (n =&hellip; <span class=\"read-more-span\"><a href=\"https:\/\/nclinnovations.org\/covid19monitor\/20-apr-2021-epabs-inm005-mortality-was-69-the-inm005-group-vs-114-in-the-placebo\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;(20 Apr 2021) EpAbs (INM005)- mortality was 6*9% the INM005 group Vs 11*4% in the placebo&#8221;<\/span> <span class=\"genericon genericon-next\"><\/span><\/a><\/span><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"bgseo_title":"","bgseo_description":"","bgseo_robots_index":"index","bgseo_robots_follow":"follow"},"categories":[6],"tags":[128],"_links":{"self":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/996"}],"collection":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/comments?post=996"}],"version-history":[{"count":1,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/996\/revisions"}],"predecessor-version":[{"id":997,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/996\/revisions\/997"}],"wp:attachment":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/media?parent=996"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/categories?post=996"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/tags?post=996"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}